Surrozen, Inc. (NASDAQ:SRZN – Get Rating) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 227,300 shares, a decline of 18.7% from the December 31st total of 279,700 shares. Approximately 1.2% of the company's stock are sold short. Based on an average daily volume of 812,000 shares, the short-interest ratio is currently 0.3 days.
Surrozen Price Performance
NASDAQ:SRZN remained flat at $0.72 during midday trading on Friday. 409,438 shares of the company traded hands, compared to its average volume of 753,427. The stock has a fifty day moving average of $0.60 and a two-hundred day moving average of $1.85. Surrozen has a 12-month low of $0.34 and a 12-month high of $3.97.
Get
Surrozen alerts:
Surrozen (NASDAQ:SRZN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. On average, sell-side analysts anticipate that Surrozen will post -1.46 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of SRZN. Bank of Montreal Can acquired a new position in Surrozen in the first quarter valued at $377,000. FMR LLC acquired a new position in Surrozen in the second quarter valued at $744,000. Board of Trustees of The Leland Stanford Junior University increased its stake in Surrozen by 3,102.9% in the third quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company's stock valued at $1,580,000 after purchasing an additional 757,546 shares during the period. Finally, Vanguard Group Inc. increased its stake in Surrozen by 3.2% in the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company's stock valued at $984,000 after purchasing an additional 15,299 shares during the period. 62.13% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
SRZN has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut shares of Surrozen from a "neutral" rating to an "underweight" rating in a research report on Tuesday, November 29th. Guggenheim cut shares of Surrozen from a "buy" rating to a "neutral" rating in a research report on Friday, November 18th. Finally, Bank of America cut shares of Surrozen from a "neutral" rating to an "underperform" rating in a research report on Wednesday, November 16th.
Surrozen Company Profile
(Get Rating)
Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Read More
- Get a free copy of the StockNews.com research report on Surrozen (SRZN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
